What is Promacta (eltrombopag) and what is it used for?
Promacta is the brand name for eltrombopag. It’s an oral medicine used to treat certain blood disorders where the body makes too few platelets (thrombocytopenia).
What does “25 mg” mean?
“Promacta 25 mg” refers to the strength of the tablet/capsule: each dose contains 25 milligrams of eltrombopag. Dose selection depends on the condition being treated and your platelet counts, which clinicians monitor to avoid excessive platelet levels.
How is Promacta typically taken?
Promacta dosing is individualized. Patients generally follow a schedule set by their clinician and get regular blood tests (especially platelet counts) to guide dose adjustments.
What side effects are associated with Promacta?
Common side effects can include headache, nausea, diarrhea, and fatigue. Because Promacta changes platelet levels, clinicians also monitor for complications tied to abnormal platelet counts.
What should patients avoid while taking eltrombopag?
Eltrombopag can interact with certain foods, supplements, or other medications that affect absorption. Clinicians usually give specific guidance on what to avoid and when to take doses.
Is Promacta affected by patents or generic competition?
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines, which can help explain when lower-cost generic or competing products may appear. You can check Promacta’s patent landscape here: DrugPatentWatch.com (Promacta/eltrombopag).
Where to go next if you mean something specific by “Promacta 25 mg”
People searching “Promacta 25 mg” often want one of these details:
- dosing instructions for a specific diagnosis,
- how to adjust the dose based on platelet counts,
- drug interactions (e.g., with supplements or other prescriptions),
- insurance cost or availability of generics.
If you tell me the condition you’re treating (for example, immune thrombocytopenia, hepatitis C–related thrombocytopenia, or aplastic anemia) and your platelet level if you know it, I can tailor the information to that use case.
Sources
- DrugPatentWatch.com (Promacta/eltrombopag)